Angiostatic effects of K252a, a Trk inhibitor, in murine brain capillary endothelial cells

Molecular and Cellular Biochemistry

Volumn 339, Issue 1-2, 2010, Pages 201-213

  Lecht, Shimon ^a   Arien Zakay, Hadar ^a   Kohan, Martin ^a   Lelkes, Peter I ^b   Lazarovici, Philip ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b DREXEL UNIVERSITY   (United States)

Author keywords

Angiostatic; K252a; K252b; Nerve growth factor; Signaling; TrkA receptor

Indexed keywords

K 252A; K 252B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE GROWTH FACTOR; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; PROTEIN TYROSINE KINASE A; CARBAZOLE DERIVATIVE; COLLAGEN; DRUG COMBINATION; ENZYME INHIBITOR; INDOLE ALKALOID; LAMININ; MATRIGEL; MESSENGER RNA; PROTEOGLYCAN; STAUROSPORINE AGLYCONE;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CAPILLARY ENDOTHELIUM; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; GROWTH INHIBITION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; CYTOLOGY; DRUG COMBINATION; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; CARBAZOLES; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; ENZYME INHIBITORS; INDOLE ALKALOIDS; LAMININ; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NERVE GROWTH FACTOR; PHOSPHORYLATION; PROTEOGLYCANS; RECEPTOR, TRKA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MURINAE;

EID: 77952293114     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-010-0386-9     Document Type: Article

References (61)

1. J Folkman 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 273 286 10.1038/nrd2115 1:CAS:528:DC%2BD2sXjs1SisL4%3D 17396134 (Pubitemid 46505878)
2. RS Herbst 2006 Therapeutic options to target angiogenesis in human malignancies Expert Opin Emerg Drugs 11 635 650 10.1517/14728214.11.4.635 1:CAS:528:DC%2BD28XhtFWltbfL 17064223 (Pubitemid 44735590)
3. L Calza L Giardino A Giuliani L Aloe R Levi-Montalcini 2001 Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors Proc Natl Acad Sci USA 98 4160 4165 10.1073/pnas.051626998 1:CAS:528: DC%2BD3MXis1KhtLg%3D 11259645 (Pubitemid 32249915)
4. B Nico D Mangieri V Benagiano E Crivellato D Ribatti 2008 Nerve growth factor as an angiogenic factor Microvasc Res 75 135 141 10.1016/j.mvr.2007.07. 004 1:CAS:528:DC%2BD1cXitVeisL0%3D 17764704 (Pubitemid 351249859)
5. Lecht S, Puxeddu I, Levi-Schaffer F, Reich R, Davidson B, Schaefer E, Marcinkiewicz C, Lelkes PI, Lazarovici P (2007) Nerve growth factor-a neurotrophin with angiogenic activity. In: Maragudakis M (ed) Angiogenesis: basic science and clinical applications. Transworld Research Network, Kerala, pp 99-113
6. P Lazarovici C Marcinkiewicz PI Lelkes 2006 Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development Curr Pharm Des 12 2609 2622 10.2174/138161206777698738 1:CAS:528:DC%2BD28XmvVCnsbs%3D 16842161
7. L Aloe P Tirassa L Bracci-Laudiero 2001 Nerve growth factor in neurological and non-neurological diseases: basic findings and emerging pharmacological prospectives Curr Pharm Des 7 113 123 10.2174/1381612013398383 1:CAS:528:DC%2BD3MXhtVGqsLk%3D 11172703 (Pubitemid 32409710)
8. A Kruttgen I Schneider J Weis 2006 The dark side of the NGF family: neurotrophins in neoplasias Brain Pathol 16 304 310 10.1111/j.1750-3639.2006. 00037.x 17107600
9. HS Singer B Hansen D Martinie CL Karp 1999 Mitogenesis in glioblastoma multiforme cell lines: a role for NGF and its TrkA receptors J Neurooncol 45 1 8 10.1023/A:1006323523437 1:STN:280:DC%2BD3c7ptFanug%3D%3D 10728904 (Pubitemid 30142435)
10. DG Menter JL Herrmann D Marchetti GL Nicolson 1994 Involvement of neurotrophins and growth factors in brain metastasis formation Invasion Metastasis 14 372 384 1:CAS:528:DyaK2MXovF2mt7c%3D 7657530
11. BA Ruggeri SJ Miknyoczki J Singh RL Hudkins 1999 Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models Curr Med Chem 6 845 857 1:CAS:528:DyaK1MXlvFWqtb0%3D 10495355
12. M Fiore GN Chaldakov L Aloe 2009 Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems Rev Neurosci 20 133 145 1:CAS:528:DC%2BD1MXhtFCkurrE 19774790
13. MH Tuszynski L Thal M Pay DP Salmon U Hoi Sang R Bakay P Patel A Blesch HL Vahlsing G Ho G Tong SG Potkin J Fallon L Hansen EJ Mufson JH Kordower C Gall J Conner 2005 A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease Nat Med 11 551 555 10.1038/nm1239 1:CAS:528: DC%2BD2MXjvVOls7s%3D 15852017 (Pubitemid 40691288)
14. G Pittenger A Vinik 2003 Nerve growth factor and diabetic neuropathy Exp Diabesity Res 4 271 285 14668049
15. L Aloe P Tirassa A Lambiase 2008 The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers Pharmacol Res 57 253 258 10.1016/j.phrs.2008.01.010 1:CAS:528:DC%2BD1cXlslKgs7c%3D 18329283
16. L Dolle I El Yazidi-Belkoura E Adriaenssens V Nurcombe H Hondermarck 2003 Nerve growth factor overexpression and autocrine loop in breast cancer cells Oncogene 22 5592 5601 10.1038/sj.onc.1206805 1:CAS:528:DC%2BD3sXmslSjtbs%3D 12944907 (Pubitemid 37102695)
17. B Davidson R Reich P Lazarovici JM Nesland M Skrede B Risberg CG Trope VA Florenes 2003 Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma Clin Cancer Res 9 2248 2259 1:CAS:528:DC%2BD3sXksVajsr0%3D 12796393
18. G Cantarella L Lempereur M Presta D Ribatti G Lombardo P Lazarovici G Zappala C Pafumi R Bernardini 2002 Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo FASEB J 16 1307 1309 1:CAS:528:DC%2BD38XlslWktb8%3D 12154004
19. Lazarovici P, Matsuda Y, Kaplan D, Guroff G (1997) The protein kinase inhibitors K252a and Staurosporine as modifiers of neurotrophin receptor signal transduction. In: Gutman Y, Lazarovici P (eds) Cellular and molecular mechanisms of toxin action: toxins and signal transduction. Harwood Academic Publishers, Amsterdam, pp 69-93
20. P Tapley F Lamballe M Barbacid 1992 K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors Oncogene 7 371 381 1:CAS:528:DyaK38XksVegsrc%3D 1312698
21. PP Roux G Dorval M Boudreau A Angers-Loustau SJ Morris J Makkerh PA Barker 2002 K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK J Biol Chem 277 49473 49480 10.1074/jbc.M203428200 1:CAS:528:DC%2BD38XpsFaks7Y%3D 12388555 (Pubitemid 36014383)
22. P Perez-Pinera T Hernandez O Garcia-Suarez F de Carlos A Germana M Del Valle A Astudillo JA Vega 2007 The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas Mol Cell Biochem 295 19 26 10.1007/s11010-006- 9267-7 1:CAS:528:DC%2BD2sXosFKisg%3D%3D 16862449 (Pubitemid 46157982)
23. A Morotti S Mila P Accornero E Tagliabue C Ponzetto 2002 K252a inhibits the oncogenic properties of Met, the HGF receptor Oncogene 21 4885 4893 10.1038/sj.onc.1205622 1:CAS:528:DC%2BD38XmtVWkt74%3D 12118367
24. N Takai T Ueda M Nishida K Nasu H Narahara 2008 K252a is highly effective in suppressing the growth of human endometrial cancer cells, but has little effect on normal human endometrial epithelial cells Oncol Rep 19 749 753 1:CAS:528:DC%2BD1cXjs1els7o%3D 18288411
25. N Takai T Ueda M Nishida K Nasu J Fukuda I Miyakawa 2005 K252a inhibits proliferation of ovarian cancer cells by upregulating p21WAF1 Oncol Rep 14 141 143 1:CAS:528:DC%2BD2MXmt1Chur0%3D 15944781
26. T Illmer G Ehninger 2007 FLT3 kinase inhibitors in the management of acute myeloid leukemia Clin Lymphoma Myeloma 8 Suppl 1 S24 S34 10.3816/CLM.2007.s.030 1:CAS:528:DC%2BD1cXhs1OgtL8%3D 18282363 (Pubitemid 351204448)
27. S Zacchigna D Lambrechts P Carmeliet 2008 Neurovascular signalling defects in neurodegeneration Nat Rev Neurosci 9 169 181 10.1038/nrn2336 1:CAS:528:DC%2BD1cXitFKnur8%3D 18253131 (Pubitemid 351272665)
28. Lecht S, Arien-Zakay H, Marcinkiewicz C, Lelkes PI, Lazarovici P (2009) Nerve growth factor-induced protection of brain capillary endothelial cells exposed to oxygen-glucose deprivation involves attenuation of Erk phosphorylation. J Mol Neurosci doi: 10.1007/s12031-12009-19318-12030
29. H Arien-Zakay S Lecht A Perets B Roszell PI Lelkes P Lazarovici 2009 Quantitative assessment of neuronal differentiation in three-dimensional collagen gels using enhanced green fluorescence protein expressing PC12 pheochromocytoma cells J Mol Neurosci 37 225 237 10.1007/s12031-008-9123-1 1:CAS:528:DC%2BD1MXpsl2ksg%3D%3D 18629654
30. H Arien-Zakay S Lecht MM Bercu R Tabakman R Kohen H Galski A Nagler P Lazarovici 2008 Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors Exp Neurol 216 83 94 10.1016/j.expneurol.2008.11.006 19070617
31. Lelkes PI, Hahn KA, Karmiol S, Schmidt DH (1998) Hypoxia/reoxygenation enhances tube formation of cultured human microvascular endothelial cells: role of reactive oxygen species. In: Maragoudakis ME (ed) Angiogenesis. Plenum Press, New York and London
32. E Papadimitriou BR Unsworth ME Maragoudakis PI Lelkes 1993 Time course and quantitation of extracellular matrix maturation in the chick chorioallantoic membrane and in cultured endothelial cells Endothelium 1 207 219 10.3109/10623329309102698
33. H Mizuguchi Y Hashioka A Fujii N Utoguchi K Kubo S Nakagawa A Baba T Mayumi 1994 Glial extracellular matrix modulates gamma-glutamyl transpeptidase activity in cultured bovine brain capillary and bovine aortic endothelial cells Brain Res 651 155 159 10.1016/0006-8993(94)90692-0 1:CAS:528:DyaK2cXltVGhs7k%3D 7922563 (Pubitemid 24222862)
34. M Kohan R Bader I Puxeddu F Levi-Schaffer R Breuer N Berkman 2007 Enhanced osteopontin expression in a murine model of allergen-induced airway remodelling Clin Exp Allergy 37 1444 1454 1:CAS:528:DC%2BD2sXht1emt7nF 17883724
35. Y Omidi L Campbell J Barar D Connell S Akhtar M Gumbleton 2003 Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies Brain Res 990 95 112 10.1016/S0006-8993(03)03443-7 1:CAS:528:DC%2BD3sXotVymurk%3D 14568334 (Pubitemid 37247600)
36. I Katzir J Shani K Regev D Shabashov P Lazarovici 2002 A quantitative bioassay for nerve growth factor, using PC12 clones expressing different levels of trkA receptors J Mol Neurosci 18 251 264 10.1385/JMN:18:3:251 1:CAS:528:DC%2BD38XktlGhurw%3D 12059044 (Pubitemid 34569416)
37. Lecht S, Foerster C, Arien-Zakay H, Marcinkiewicz C, Lazarovici P, Lelkes PI (2009) Cardiac microvascular endothelial cells express and release nerve growth factor but not fibroblast growth factor-2. In Vitro Cell Dev Biol Anim doi: 10.1007/s11626-11009-19267-11625
38. H Kim Q Li BL Hempstead JA Madri 2004 Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells J Biol Chem 279 33538 33546 10.1074/jbc. M404115200 1:CAS:528:DC%2BD2cXmtFOitb4%3D 15169782 (Pubitemid 39063002)
39. DR Kaplan FD Miller 2000 Neurotrophin signal transduction in the nervous system Curr Opin Neurobiol 10 381 391 10.1016/S0959-4388(00)00092-1 1:CAS:528:DC%2BD3cXks1Kltb0%3D 10851172 (Pubitemid 30389307)
40. K Ohmi S Yamashita Y Hashimoto Y Nonomura 1993 Induction of giant endothelial cells in culture by K-252a, a protein kinase inhibitor Jpn J Pharmacol 63 195 202 10.1254/jjp.63.195 1:CAS:528:DyaK2cXivVaksQ%3D%3D 8283830
41. D Vaudry PJ Stork P Lazarovici LE Eiden 2002 Signaling pathways for PC12 cell differentiation: making the right connections Science 296 1648 1649 10.1126/science.1071552 1:CAS:528:DC%2BD38XktlCht7Y%3D 12040181 (Pubitemid 34579153)
42. C Hartmann A Zozulya J Wegener HJ Galla 2007 The impact of glia-derived extracellular matrices on the barrier function of cerebral endothelial cells: an in vitro study Exp Cell Res 313 1318 1325 10.1016/j.yexcr.2007.01.024 1:CAS:528:DC%2BD2sXjvFGrs7k%3D 17346702 (Pubitemid 46507445)
43. DS Grant PI Lelkes K Fukuda HK Kleinman 1991 Intracellular mechanisms involved in basement membrane induced blood vessel differentiation in vitro In Vitro Cell Dev Biol 27A 327 336 10.1007/BF02630910 1:STN:280: DyaK3MzhtVGmtA%3D%3D 1856158
44. E Papadimitriou CR Waters VG Manolopoulos BR Unsworth ME Maragoudakis PL Lelkes 2001 Regulation of extracellular matrix remodeling and MMP-2 activation in cultured rat adrenal medullary endothelial cells Endothelium 8 181 194 10.3109/10623320109051564 1:CAS:528:DC%2BD38XlvFOluw%3D%3D 11824471 (Pubitemid 34056068)
45. N Utoguchi K Ikeda K Saeki N Oka H Mizuguchi K Kubo S Nakagawa T Mayumi 1995 Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer J Cell Physiol 163 393 399 10.1002/jcp.1041630219 1:CAS:528: DyaK2MXkvFWntr8%3D 7706381
46. H Ashino M Shimamura H Nakajima M Dombou S Kawanaka T Oikawa T Iwaguchi S Kawashima 2003 Novel function of ascorbic acid as an angiostatic factor Angiogenesis 6 259 269 10.1023/B:AGEN.0000029390.09354.f8 1:CAS:528: DC%2BD2cXktlyktL0%3D 15166494 (Pubitemid 38987535)
47. KV Moser M Reindl I Blasig C Humpel 2004 Brain capillary endothelial cells proliferate in response to NGF, express NGF receptors and secrete NGF after inflammation Brain Res 1017 53 60 10.1016/j.brainres.2004.05.013 1:CAS:528:DC%2BD2cXlsl2jtbo%3D 15261099 (Pubitemid 38917143)
48. AV Andjelkovic SM Stamatovic RF Keep 2003 The protective effects of preconditioning on cerebral endothelial cells in vitro J Cereb Blood Flow Metab 23 1348 1355 10.1097/01.WCB.0000091762.61714.FE 1:CAS:528:DC%2BD3sXos1Cmtbw%3D 14600442
49. VL Thijssen JR van Beijnum KH Mayo AW Griffioen 2007 Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango Curr Pharm Des 13 3576 3583 10.2174/138161207782794121 1:CAS:528: DC%2BD1cXnsVOhtA%3D%3D 18220794 (Pubitemid 350238928)
50. M Satoh N Kokubu K Matsuo I Takayanagi 1995 Alpha 1A-adrenoceptor subtype effectively increases Ca(2+)-sensitivity for contraction in rabbit thoracic aorta Gen Pharmacol 26 357 362 10.1016/0306-3623(94)00198-V 1:CAS:528: DyaK2MXkvVSjs7Y%3D 7590087
51. K Ohmi S Yamashita Y Nonomura 1990 Effect of K252a, a protein kinase inhibitor, on the proliferation of vascular smooth muscle cells Biochem Biophys Res Commun 173 976 981 10.1016/S0006-291X(05)80881-2 1:CAS:528: DyaK3MXnsV2lsQ%3D%3D 2268357
52. S Miura Y Matsuo K Saku 2004 Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling Atherosclerosis 175 235 243 10.1016/j.atherosclerosis.2004.04.017 1:CAS:528:DC%2BD2cXlsl2gt7g%3D 15262179 (Pubitemid 38942903)
53. YH Yang Y Wang KS Lam MH Yau KK Cheng J Zhang W Zhu D Wu A Xu 2008 Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4 Arterioscler Thromb Vasc Biol 28 835 840 10.1161/ATVBAHA.107.157776 1:CAS:528:DC%2BD1cXktlylsL4%3D 18340008 (Pubitemid 351544096)
54. SP Tabruyn AW Griffioen 2007 Molecular pathways of angiogenesis inhibition Biochem Biophys Res Commun 355 1 5 10.1016/j.bbrc.2007.01.123 1:CAS:528:DC%2BD2sXitFOmt78%3D 17276388 (Pubitemid 46273381)
55. AS Ali S Ali BF El-Rayes PA Philip FH Sarkar 2009 Exploitation of protein kinase C: a useful target for cancer therapy Cancer Treat Rev 35 1 8 10.1016/j.ctrv.2008.07.006 1:CAS:528:DC%2BD1MXhtlSmtbc%3D 18778896
56. A Grothey E Galanis 2009 Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nat Rev Clin Oncol 6 507 518 10.1038/nrclinonc. 2009.110 1:CAS:528:DC%2BD1MXhtVKjsrjJ 19636328
57. YN Abdiche DS Malashock J Pons 2008 Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors Protein Sci 17 1326 1335 10.1110/ps.035402.108 1:CAS:528:DC%2BD1cXpsVyju78%3D 18505735
58. S Wilhelm C Carter M Lynch T Lowinger J Dumas RA Smith B Schwartz R Simantov S Kelley 2006 Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 835 844 10.1038/nrd2130 1:CAS:528:DC%2BD28XhtVajsbbM 17016424 (Pubitemid 44480537)
59. S Faivre G Demetri W Sargent E Raymond 2007 Molecular basis for sunitinib efficacy and future clinical development Nat Rev Drug Discov 6 734 745 10.1038/nrd2380 1:CAS:528:DC%2BD2sXpslaksL8%3D 17690708 (Pubitemid 47338181)
60. A Quintas-Cardama J Cortes 2008 Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases Future Oncol 4 611 621 10.2217/14796694.4.5.611 1:CAS:528:DC%2BD1cXht1Glu7fI 18922118
61. C Festuccia P Muzi GL Gravina D Millimaggi S Speca V Dolo E Ricevuto C Vicentini M Bologna 2007 Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro Int J Oncol 30 193 200 1:CAS:528:DC%2BD2sXhtFyrtbg%3D 17143529